Dermata Therapeutics, Inc.

NasdaqCM DRMA

Dermata Therapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Dermata Therapeutics, Inc. Operating Income Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqCM: DRMA

Dermata Therapeutics, Inc.

CEO	Mr. Gerald T. Proehl
IPO Date	Aug. 13, 2021
Location	United States
Headquarters	3525 Del Mar Heights Road
Employees	8
Sector	Consumer Discretionary
Industries Cosmetics Biotechnology Clinical Trials Eyewear Personal Care Pharmaceuticals

Description

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Key trends

Past 5 years